Germany’s DZNE launched NeuroGenomeHub, a brain genomics initiative funded with about €6 million to build a global genome database for neurodegenerative diseases. The program plans to sequence samples from roughly 25,000 individuals over the next two years, including those from ongoing DZNE studies such as the Rhineland population project. DZNE said the database will leverage blood and other sample types, incorporate long-read sequencing, and use DNA methylation analyses to refine risk and progression signals. The effort aims to identify genome and epigenome features linked to disorders including Alzheimer’s, Parkinson’s, and Huntington’s. DZNE scientific director Joachim Schultze said the project is intended to enable new diagnostics, prevention, and therapeutic approaches by improving understanding of genetic drivers of disease risk and progression.